胎儿新生儿溶血病实验室检测专家共识*

doi:10.3969/j.issn.1671-2587.2021.01.006

临床输血与检验 ›› 2021, Vol. 23 ›› Issue (1): 20-24.DOI: 10.3969/j.issn.1671-2587.2021.01.006

胎儿新生儿溶血病实验室检测专家共识^*

中国输血协会免疫血液学专业委员会

100142 北京,空军特色医学中心输血科

收稿日期:2020-10-02 发布日期:2021-02-22
作者简介:执笔作者：李翠莹（1969-）,女,陕西礼泉人,主任技师,硕士研究生导师,主要从事临床输血与免疫血液学研究,（E-mail）licuiying2013@qq.com;李小薇（1986-）,女,主管技师,博士,主要从事临床输血相关研究,（E-mail）lixiaowei0825@126.com。
基金资助:
*本课题受全军重点项目分课题（No.BWS16J006-03-01）资助

Received:2020-10-02 Published:2021-02-22

摘要/Abstract

摘要： 针对国际上对胎儿新生儿溶血病（hemolytic disease of the fetus and newborn,HDFN）的发病机制、实验室诊断和治疗研究取得的进展,中国输血协会免疫血液学专业委员会组织专家根据国内前期调研HDFN实验室的具体发展现状,制定了此专家共识,对我国HDFN实验室检测项目、检测方法及抗体筛选时机、频次及质量控制方面的要点进行梳理并确定检测方案,目的是进一步规范HDFN实验室操作,提高我国从事HDFN实验室人员的技术水平。

中图分类号:

R556.6R446.61

中国输血协会免疫血液学专业委员会. 胎儿新生儿溶血病实验室检测专家共识^*[J]. 临床输血与检验, 2021, 23(1): 20-24.

参考文献

[1] DE HAAS M,THURIK F F,KOELEWIJN J M,et al.Haemolytic disease of the fetus and newborn[J].Vox Sang,2015,109(2):99-113.
[2] LI S,HE Z M,LUO Y M,et al.Distribution of maternal red cell antibodies and the risk of severe alloimmune haemolytic disease of the foetus in a Chinese population:a cohort study on prenatal management[J].BMC Pregnancy Childbirth,2020,20:539.
[3] WEBB J,DELANEY M.Red blood cell alloimmunizati on in the pregnant patient[J].Transfus Med Rev,2018,32(4):213-219.
[4] BEL HADJ I,BOUKHRIS R,KHALSI F,et al.ABO hemolytic disease of newborn:Does newborn's blood group a risk factor?[J].La Tunisie Med,2019,97(3):455-460.
[5] ZONNEVELD R,VAN DER MEER-KAPELLE L,SYLVA M,et al.Severe fetal hemolysis and cholestasis due to high-titer maternal IgG anti-A antibodies[J].Pediatrics,2019,143(4):e20182859.DOI:10.1542/peds.2018-2859.
[6] DAJAK S,IPAVEC N,CUK M,et al.The outcome of hemolytic disease of the fetus and newborn caused by anti-Rh17 antibody:analysis of three cases and review of the literature[J].Transfus Med Hemother,2020,47(3):264-271.
[7] DAJAK SLAVICA,CULICSRCANA,STEFANOVIC VEDRAN, et al.Relationship between previous maternal transfusions and haemolytic disease of the foetus and newborn mediated by non-RhD antibodies[J]. Blood Transfus, 2013, 11(4): 528-532.
[8] DENOMME H A,NOLLET S E.Three non-classical mechanisms for anemic disease of the fetus and newborn,based on maternal anti-Kell,anti-Ge3,anti-M,and anti-Jra cases[J].Transfus Apher Sci,2020,59(5):102949.
[9] LI S,MO C Y,HUANG L H,et al.Hemolytic disease of the fetus and newborn due to alloanti-M:three Chinese case reports and a review of the literature[J].Transfusion,2019,59(1):385-395.
[10] WHITE J,QURESHI H,MASSEY E,et al.Guideline for blood grouping and red cell antibody testing in pregnancy[J].Transfusion Med,2016,26(4):246-263.
[11] Royal College of Obstetricians and Gynaecologists (RCOG).Green-top guideline no.65:the management of women with red cell antibodies during pregnancy[J].Obstet Gynecol,2014,16(3):224.
[12] National Institute for Biological Standards and Control. Anti-D for assuring operator and test performance (NIBSC code: 07/304)[EB/OL].(2010-06-21). https://www.nibsc.org/products/brm_product_catalogue/detail_page.aspx?catid=07/304.
[13] National Institute for Biological Standards and Control. Anti-c Serum, Human (NIBSC code: 84/628)[EB/OL].(2015-11-19). https://www.nibsc.org/products/brm_product_catalogue/detail_page.aspx?catid=84/628.
[14] 肖军,郑飞天,陈柄澔,等.O型孕产妇IgG抗体效价与胎儿新生儿溶血病关系的Meta分析[J]. 中国输血杂志, 2020, 33(9): 925-928.
[15] LUCAS G F,HADLEY A G,NANCE S J,et al.Predicti ng hemolytic disease of the newborn:a comparison of the monocyte monolayer assay and the chemiluminescence test[J].Transfusion,1993,33(6):484-487.
[16] BREVEGLIERI G,D'AVERSA E,FINOTTI A,et al.Non-invasive prenatal testing using fetal DNA[J].Mol Diagn Ther,2019,23(2):291-299.
[17] QURESHI H,MASSEY E,KIRWAN D,et al.BCSH guideline for the use of anti-D immunoglobulin for the prevention of haemolytic disease of the fetus and newborn[J].Transfusion Med,2014,24(1):8-20.
[18] WYLIE B J,D'ALTON M E.Fetomaternal hemorrhage[J].Obstet Gynecol,2010,115(5):1039-1051.
[19] KIM Y A,MAKAR R S.Detection of fetomaternal hemorrhage[J].Am J Hematol,2012,87(4):417-423.
[20] BELLUSSI F,PEROLO A,GHI T,et al.Diagnosis of severe fetomaternal hemorrhage with fetal cerebral Doppler:case series and systematic review[J].Fetal Diagn Ther,2017,41(1):1-7.
[21] 马克•K.冯,布伦达•J.格罗斯曼,克里斯托弗•D.希利尔, 等主编.桂嵘,陈秉宇,黄远帅,等主译.AABB技术手册[M]. 第18版. 长沙: 中南大学出版社,2019: 646-647.
[22] 马印图,王更银,李玉秋,等.微柱凝胶技术检测血型抗体IgG亚型试验方法的建立[J]. 临床血液学杂志(输血与检验),2018,31(2):253-256.
[23] American College of Obstetricians and Gynecologists' Committee on Practice Bulletins—Obstetrics.ACOG Practice Bulletin No. 192: Management of Alloimmunization During Pregnancy[J].Obstet Gynecol, 2018; 131(3):e82-e90.
[24] MOISE K J JR,ARGOTI P S.Management and prevention of red cell alloimmunization in pregnancy[J].Obstet Gynecol,2012,120(5):1132-1139.

胎儿新生儿溶血病实验室检测专家共识^*

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 7

编辑推荐

Metrics

本文评价

关于本刊

作者中心

在线期刊

访问统计

联系我们

[1]	北京医学会输血医学分会, 北京医师协会输血专业专家委员会. 中国输血医师规范化培训实施方案专家共识[J]. 临床输血与检验, 2021, 23(1): 1-5.
[2]	李翠莹. 胎儿新生儿溶血病的诊疗策略探讨^*[J]. 临床输血与检验, 2021, 23(1): 24-28.
[3]	范秀, 肖军, 李翠莹. 抗-D免疫球蛋白预防RhD血型不合胎儿新生儿溶血病的研究进展^*[J]. 临床输血与检验, 2021, 23(1): 29-32.
[4]	雷慧芬, 樊凤艳, 肖军, 李小薇, 李翠莹. 国内医疗机构胎儿新生儿溶血病免疫血液学检测情况分析^*[J]. 临床输血与检验, 2021, 23(1): 33-38.
[5]	中国医师协会输血科医师分会. 医疗机构中乙型肝炎病毒、丙型肝炎病毒、人类免疫缺陷病毒(1+2型)核酸检测策略专家共识[J]. 临床输血与检验, 2020, 22(6): 561-564.
[6]	魏亚明, 桂嵘, 王秋实, 刘志伟. 血小板抗体检测专家共识[J]. 临床输血与检验, 2020, 22(1): 1-5.
[7]	胡晓玉, 吴学忠. TP主要膜蛋白研究及梅毒实验检测方法应用进展[J]. 临床输血与检验, 2018, 20(1): 108-110.